GHAM
DNA icon

Gilman Hill Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Gilman Hill Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250
Closed -$3.34K – 228
2024
Q2 		$3.34K Hold
250
– – ﹤0.01% 213
2024
Q1 		$11.6K Hold
250
– – ﹤0.01% 213
2023
Q4 		$16.9K Sell
250
-125
-33% -$7.65K ﹤0.01% 211
2023
Q3 		$27.1K Buy
375
+125
+50% +$9.99K 0.01% 205
2023
Q2 		$18.6K Buy
+250
New +$14.8K ﹤0.01% 214

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gilman Hill Asset Management's DNA Position: Q3 2024 in Review

Gilman Hill Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 250 shares — an estimated $3.34K sold.

Gilman Hill Asset Management first reported a position in DNA in Q2 2023 and held it in 5 quarters. The position peaked at $27.1K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Gilman Hill Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Gilman Hill Asset Management sold 250 Ginkgo Bioworks shares in Q3 2024, an estimated $3.34K.
  • Gilman Hill Asset Management first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 5 quarters.
  • Gilman Hill Asset Management's Ginkgo Bioworks position peaked at $27.1K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Gilman Hill Asset Management's 13F filing for Q3 2024, filed 10 Oct 2024.